Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Myovant Sciences to Present at Upcoming Investor Conferences
08:30am, Tuesday, 01'st Jun 2021
BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to
Myovant - Pfizer's Uterine Fibroids Treatment Wins FDA Approval
08:15am, Thursday, 27'th May 2021
The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc's (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibr
LONDON and NEW YORK, May 26, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovan
Myovant Sciences' Relugolix Combo Tablet For Uterine Fibroids Scores EMA Backing For Approval
03:52pm, Friday, 21'st May 2021
European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix, estradiol, and norethindrone acetate) fo
BASEL, Switzerland, May 21, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopt
Myovant Stock Is Trading Lower After FDA Slapped Clinical Hold On Relugolix Combo Study
08:03am, Wednesday, 19'th May 2021
Myovant Sciences Ltd (NYSE: MYOV) has received a partial clinical hold on its SERENE study (MVT-601-050) from the FDA. The Phase 3 study was evaluating relugolix combination tablets for the prevent
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2020 Results - Earnings Call Transcript
12:44pm, Tuesday, 11'th May 2021
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2020 Results - Earnings Call Transcript
Myovant Sciences (MYOV) Reports Q4 Loss, Tops Revenue Estimates
09:01am, Tuesday, 11'th May 2021
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 10.10% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
05:58pm, Sunday, 09'th May 2021
The FDA is currently reviewing the relugolix combination therapy for symptoms of Uterine Fibroids and set a PDUFA date on 6/1/2021. Myovant is currently successfully launching its first approved produ
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
06:11pm, Tuesday, 13'th Apr 2021
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
06:58am, Monday, 05'th Apr 2021
BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren
BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Age
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
09:06am, Thursday, 25'th Mar 2021
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.
BASEL, Switzerland and NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced positive data from the Phase 3 LIBERTY randomized withdra
Myovant Sciences to Present at Upcoming Investor Conferences
08:30am, Monday, 22'nd Feb 2021
BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to
